Avaxia Biologics
Avaxia Biologics develops orally-delivered antibody therapeutics using a proprietary antibody platform
About Avaxia Biologics
Avaxia Biologics, now under Circle33, specializes in the development of orally administered, gut-targeted antibody therapeutics. The company focuses on creating gastrointestinal (GI) stable recombinant monoclonal antibodies, which are designed to treat inflammatory conditions with minimal systemic exposure and low immunogenicity. Avaxia's flagship product, AVX 470, a bovine polyclonal milk-derived anti-TNF antibody, has demonstrated promising results in a Phase 1b clinical trial for ulcerative colitis (UC). The company operates in the biopharmaceutical market, targeting both adult and pediatric inflammatory bowel disease (IBD), a market estimated to be worth approximately $9 billion worldwide. Avaxia's business model includes selling or licensing its technology for commercialization, leveraging its strong intellectual property portfolio and significant investment in research and development. The company generates revenue through these business arrangements and aims to address unmet medical needs in the GI therapeutic space.
Source: Dealroom company dataNews
Open roles
Avaxia Biologics in the Lexington ecosystem
The Avaxia Biologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- FAFort Point Angels
Maine Angels
Beta Fund
Golden Seeds
Series B and later1 investor entered at this stage
- CACherrystone Angels
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Avaxia Biologics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Avaxia Biologics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


